Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on PARP Inhibition for Prostate Cancer

In this podcast episode, listen to Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, as they answer questions from a healthcare professional audience on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Charles J. Ryan, MD
Neal D. Shore, MD, FACS
Released: April 6, 2021

In this episode, Charles J. Ryan, MD; and Neal D. Shore, MD, FACS; answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

  • Germline and somatic mutation testing
  • Managing adverse events with PARP inhibitors
  • Resistance to PARP inhibitors
  • Implications of monoallelic vs biallelic BRCA mutations
  • ATM mutations and PARP inhibitor sensitivity

Presenters:

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 5, 2022

Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).

Katy E. Beckermann, MD, PhD Released: June 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings